

BOOKSContributor of Chapters

1. **Behnke M**, Nackashi JA, Raulerson MD, Schuler PM, Mehta P: The pediatrician and the dying child. In: Wass, H.; Corr, C.A. (eds): Childhood and Death. New York: Hemisphere, pp 69-93, 1984.
2. **Behnke M**: Pulmonary assessment of pediatric patients. In: Eitzman DV, Koff P, Kopotic R, Neu J (eds): Neonatal and Pediatric Respiratory Care. St. Louis: C.V. Mosby, pp 26-43, 1988.
3. Anderson GC, **Behnke M**, Gill NE, Conlon M, Measel CP, McDonie TE: Self-regulatory gavage-to-bottle feeding for preterm infants: Effects on behavioral state, energy expenditure, and weight gain. In: Funk SG, Tornquist EM, Champagne MT, Copp LA, Wiese RA (eds): Key Aspect of Recovery: Improving Nutrition, Rest, and Mobility. New York: Springer, pp 83-97, 1990.
4. **Behnke M**, Koff PB: Patient Assessment. In: Koff PB, Eitzman DV, Neu J (eds): Neonatal and Pediatric Respiratory Care, 2nd ed. St. Louis: C.V. Mosby, pp 31-52, 1993.
5. Woods NS, **Behnke M**, Eyler FD, Conlon M, Wobie K: Cocaine use among pregnant women: Socioeconomic, obstetrical, and psychological issues. In: Lewis M, Bendersky M (eds): Mothers, Babies, and Cocaine: The Role of Toxins in Development. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc., pp 305 - 332, 1995.

REFEREED PUBLICATIONS

1. Neimeyer GJ, **Behnke M**, Reiss J: Constructs and coping: Physicians' responses to patient death. Death Education 7(2):245-264, 1983.
2. **Behnke M**, Setzer E, Mehta P: Death counseling and psycho-social support by physicians concerning dying children. J Med Educ 59(11):906-908, 1984.
3. Hardt N, Kostenbauder M, Ogburn M, **Behnke M**, Resnick M, Cruz A: Influence of chorioamnionitis on long-term prognosis in low birthweight infants. Obstet & Gynecol 65(1):5-10, 1985.
4. Swingle H, **Behnke M**, Bucciarelli RL: Acquired arteriovenous malformation resulting from greater saphenous vein venipuncture. Clin Pediatr 24(2):88, 1985.
5. **Behnke M**, Reiss J, Neimeyer G, Setzer E: Grief Responses of pediatric house officers to a patient's death. Death Studies 11:169-176, 1987.
6. **Behnke M**, Carter RS, Hardt N, Eyler FD, Cruz A, Resnick MB: The relationship of Apgar scores, gestational age, and birthweight to survival of low-birthweight infants. Am J Perinatol 4:121-124, 1987.
7. Cruz AC, Frentzen BH, **Behnke M**: Hepatitis B: A case for prenatal screening of all patients. Am J Obstet Gynecol 156(5):1180-1183, 1987.
8. Gill NE, **Behnke M**, Conlon M, McNeely JB, Anderson GC: Effect of nonnutritive sucking on behavioral state in preterm infants before feeding. Nurs Res 37:347-350, 1988.
9. **Behnke M**, Eyler FD, Carter RL, Hardt NS, Cruz AC, Resnick MB: Predictive value of Apgar scores for developmental outcome in premature infants. Am J Perinatol 6:18-21, 1989.

10. Adams C, Eyler FD, **Behnke M**: Nursing intervention with mothers who are substance abusers. J Perinat Neonatal Nurs 3:43-52, 1990.
11. Gill NE, **Behnke M**, Conlon M, Anderson GC: Nonnutritive sucking modulates behavioral state for preterm infants before feeding. Scand J Caring Sci 6(1):3-7, 1992.
12. Woods NS, Eyler FD, **Behnke M**, Conlon M: Cocaine use during pregnancy: Maternal depressive symptoms and infant neurobehavior over the first month. Infant Behav Dev 16:83-98, 1993.
13. **Behnke M**, Eyler FD, Conlon M, Woods NS, Thomas V: The relationship between umbilical cord and infant blood gases and developmental outcome in very low birth weight infants. Clin Obstet Gynecol 36:73-81, 1993.
14. **Behnke M**, Eyler FD: The consequences of prenatal substance use for the developing fetus, newborn, and young child. Int J Add 28:1341-1391, 1993.
15. Lombardero N, Casanova O, **Behnke M**, Eyler FD, Bertholf RL: Measurement of cocaine and metabolites in urine, meconium, and diapers by gas chromatography/mass spectrometry. Ann Clin Lab Sci 23(5):385-394, 1993.
16. Meetze WH, Palazzolo V, Bowling D, **Behnke M**, Burchfield DJ, Neu J: Meconium passage in the micropremie: Effect of hypocaloric enteral priming. JPEN 17:537-540, 1993.
17. Eyler FD, **Behnke M**, Conlon M, Woods NS, Frentzen B: Prenatal cocaine use: A comparison of neonates matched on maternal risk factors. Neurotoxicol Teratol 16:81-87, 1994.
18. **Behnke M**, Eyler FD: Issues in prenatal cocaine use research: Problems in identifying users and an appropriate comparison group. Infant Mental Health J 15:146-157, 1994.
19. Casanova OQ, Lombardero N, **Behnke M**, Eyler FD, Conlon M, Bertholf RL: Detection of cocaine exposure in the neonate: Analyses of urine, meconium, and amniotic fluid from mothers and infants exposed to cocaine. Arch Pathol Lab Med 118:988-993, 1994.
20. **Behnke M**, Eyler FD, Conlon M, Woods NS, Casanova OQ: Multiple risk factors do not identify cocaine use in rural obstetrical patients. Neurotoxicol Teratol 16:479-484, 1994.
21. Worthington-White DA, **Behnke M**, Gross S: Premature infants require additional folate and vitamin B-12 to reduce the severity of the anemia of prematurity. Am J Clin Nutr 60:930-935, 1994.
22. Carter RL, **Behnke M**, Ariet M, Dickman H, Resnick MB: An index for early assessment of neonatal survival in low birthweight infants: An alternative to Apgar scores. Am J Perinatol 12:392-395, 1995.
23. Eyler FD, **Behnke M**: Prenatal cocaine exposure: Consequences for child and family. J Fla Med Assoc 82:603-606, 1995.
24. **Behnke M**, Eyler FD, Conlon M, Casanova OQ, Woods NS: How fetal cocaine exposure increases neonatal hospital costs. Pediatrics 99: 204-208, 1997.
25. Wineker RE, Goldberger BA, Tebbett IR, **Behnke M**, Eyler FD, Wobie K, Karlix J, Conlon M, and Bertholf R: Detection of cocaine and its metabolites in amniotic fluid and umbilical cord tissue. J Analytical Toxicology 21: 97-104, 1997.
26. **Behnke M**, Eyler FD, Woods NS, Wobie K, Conlon M: Rural pregnant cocaine users: An in-depth sociodemographic comparison. J Drug Issues 27:501-524, 1997.

27. Wobie K, Eyler FD, Conlon M, Clarke L, **Behnke M**: Women and children in residential treatment: Outcomes for mothers and their infants. J Drug Issues 27:585-606, 1997.
28. Wobie K, Eyler FD, **Behnke M**, Conlon M: Symbolic expression of feelings and depressive symptoms in high-risk pregnant women. J Fla Med Assoc. 84:384-390, 1997.
29. Eyler FD, **Behnke M**, Conlon M, Woods NS, Wobie K: Birth outcome from a prospective matched study of prenatal crack/cocaine use. Part I: Interactive and dose effects on health and growth. Pediatrics 101:229-237, 1998.
30. Eyler, FD, **Behnke M**, Conlon M, Woods NS, Wobie K: Birth outcome from a prospective, matched study of prenatal crack/cocaine use. Part II: Interactive and dose effects on neurobehavioral assessment. Pediatrics 101:237-241, 1998.
31. **Behnke M**, Eyler FD, Conlon M, Wobie K, Woods NS, Cumming W: Incidence and description of structural brain abnormalities in cocaine-exposed newborns. J Pediatrics 132:291-294, 1998.
32. Woods NS, Eyler FD, Conlon M, **Behnke M**, Wobie K: Pygmalion in the cradle: Observer bias against cocaine-exposed infants. J Dev Behav Pediatr 19:283-285,1998.
33. Karlix JL, **Behnke M**, Eyler FD, Wobie K, Adams V, Freiburger B, Conlon M, Tebbett IR: Perinatal cocaine suppresses the fetal immune system. Pediatr Res 44:43-46, 1998.
34. **Behnke M**, Eyler FD, Garvan CW, Tenholder M, Wobie K, Woods NS, Conlon M, Cumming W: Cranial ultrasound abnormalities identified at birth: Their relationship to perinatal risk and neurobehavioral outcome. Pediatrics 103:e41, 1999.
35. Eyler FD, **Behnke M**: Early development of infants exposed to drugs prenatally. Clinics Perinatol 26:107-150, 1999.
36. Eyler FD, **Behnke M**, Woods NS, Wobie K: Examiner masking in research on the effects of prenatal cocaine exposure. J Drug Issues 29:215-224, 1999.
37. **Behnke M**, Eyler FD, Garvan CW, Wobie K: The search for congenital malformations in newborns with fetal cocaine exposure. Pediatrics 107:e74, 2001.
38. Winecker RE, Goldberger BA, Tebbett IR, **Behnke M**, Eyler FD, Karlix JL, Wobie K, Conlon M, Phillips D, Bertholf R: Detection of cocaine and its metabolites in breast milk. J Forensic Sci 46:1221-1223, 2001.
39. Eyler FD, **Behnke M**, Garvan C, Woods NS, Wobie K, Conlon M: Neonatal evaluations of toxicity and withdrawal related to prenatal cocaine exposure. Neurotoxicol Teratol 23:399-411, 2001.
40. **Behnke M**, Eyler FD, Garvan CW, Wobie K, Hou W: Cocaine exposure and developmental outcome from birth to six months. Neurotoxicol Teratol 24:283-295, 2002.
41. Saxonhouse MA, **Behnke M**, Williams JL, Richards D, Weiss MD: Mucopolysaccharidosis type VII presenting with isolated neonatal ascites. J Perinatol 23:73-75, 2003.
42. Wobie K, Eyler FD, Garvan CG, Hou W, **Behnke M**: Prenatal cocaine exposure: An examination of mother/infant separation during the first year of life. J Drug Issues 34:77-94, 2004.

43. Hou W, Wang Z, Garvan CW, **Behnke M**, Eyler FD, Wu R: A generalized model for detecting genetic determinants underlying longitudinal traits with unequally spaced measurements and time-dependent correlated errors. BioStatistics 6:420-433, 2005.
44. Eyler FD, **Behnke M**, Garvan CW, Wobie K, Tebbett I: Relative ability of biologic specimens and interviews to detect prenatal cocaine use. Neurotoxicol Teratol 27:677-687, 2005.
45. **Behnke M**, Eyler FD, Warner TD, Garvan CW, Hou W, Wobie K: Outcome from a prospective, longitudinal study of prenatal cocaine use: Preschool development at three years of age. J Pediatr Psychol 31:41-49, 2006.
46. Dow-Edwards DL, Benveniste H, **Behnke M**, Bandstra ES, Singer LT, Hurd YL, Stanford LR: Neuroimaging of prenatal drug exposure. Neurotoxicol Teratol 28:386-402, 2006.
47. Warner TD, **Behnke M**, Eyler FD, Garvan CW, Hou W, Wobie K: Predicting caregiver reported behavior problems in cocaine-exposed children at 3 years. J Behav Dev Pediatr 27:83-92, 2006.
48. Warner TD, **Behnke M**, Eyler FD, Padgett K, Leonard CM, Hou W, Garvan CW, Schmalfuss IM, Blackband SJ: Diffusion Tensor Imaging of Frontal White Matter and Executive Functioning in Cocaine-Exposed Children Pediatrics 118:2014-2024, 2006.
49. Hou W, Garvan CW, Littell RC, **Behnke M**, Eyler FD, Wu R: A framework to monitor environment-induced major genes for developmental trajectories: Implication for a prenatal cocaine exposure study. Statistics in Medicine 25:4020-4035, 2006.
50. Eyler FD, Warner, TD, **Behnke M**, Hou W, Wobie K, Garvan CW: Executive Functioning at Ages 5 and 7 in Children with Prenatal Cocaine Exposure. Dev Neurosci 31:121-136, 2009.
51. Warner TD, **Behnke M**, Eyler FD, Szabo N, Algina J: Early Adolescent Cocaine Use as Determined by Hair Analysis in a Prenatal Cocaine Exposure Cohort. Neurotoxicol Teratol 33:88-99, 2011.
52. Roussotte F, Soderberg L, Warner T, Narr K, Lebel C, **Behnke M**, Eyler F, Sowell E: Adolescents with Prenatal Cocaine Exposure Show Subtle Alterations in Striatal Surface Morphology and Frontal Cortical Volumes. J Neurodev Disorders 4:1-10, 2012.
53. Lebel C, Warner T, Colby J, Soderberg L, Roussotte F, **Behnke M**, Eyler FD, Sowell ER: White Matter Microstructure Abnormalities and Executive Function in Adolescents with Prenatal Cocaine Exposure. Psychiatry Research: Neuroimaging 213:161-68, 2013. doi.org/10.1016/j.psychresns.2013.04.002 (PMID:23769420)
54. Warner T, Roussos-Ross D, **Behnke M**: It's Not Your Mother's Marijuana: Effects on Maternal-Fetal Health and the Developing Child. Clinics Perinatol 41:877-894, 2014. [doi:10.1016/j.clp.2014.08.009](https://doi.org/10.1016/j.clp.2014.08.009)